Platyphyllina hydrtartrate solution 0.2%, 1ml No. 10

• Peptic ulcer and duodenal ulcer, pylorospasm, cholecystitis, cholelithiasis, intestinal colic, renal colic, biliary colic;

• bronchial asthma (to prevent broncho- and laryngospasm), bronchorrhea;

• algodismenorrhea;

• spasm of the cerebral arteries;

• angiotrophoneurosis;

• arterial hypertension, angina pectoris (as part of combination therapy).

• Dilation of the pupil for diagnostic purposes (including examination of the fundus, determination of the true refraction of the eye);

• acute inflammatory eye diseases (including iritis, iridocyclitis, keratitis), eye injuries.

S / c - 2-4 mg 3 times a day. The highest single dose is 10 mg, the daily dose is 30 mg.

Solution for subcutaneous administration 0.2% 1 ml

Platyphylline hydrotartrate 2 mg

Hypersensitivity to platyphyllin.

pharmachologic effect

Blocker of m-cholinergic receptors. Compared with atropine, it has a less pronounced effect on peripheral m-cholinergic receptors (in terms of its effect on smooth muscle cells of the gastrointestinal tract and the circular muscle of the iris, it is 5-10 times weaker than atropine). By blocking m-cholinergic receptors, it disrupts the transmission of nerve impulses from postganglionic cholinergic nerves to the effector organs and tissues innervated by them (heart, smooth muscle organs, glands of external secretion); also suppresses n-cholinergic receptors (much weaker). The anticholinergic effect is more pronounced against the background of an increased tone of the parasympathetic part of the autonomic nervous system or the action of m-anticholinergics.

To a lesser extent than atropine, it causes tachycardia, especially when used in high doses. By reducing the influence of n.vagus, it improves the conductivity of the heart, increases the excitability of the myocardium, and increases the minute volume. It has a direct myotropic antispasmodic effect, causes the expansion of small vessels of the skin. In high doses, it inhibits the vasomotor center and blocks the sympathetic ganglia, as a result of which the vessels expand and blood pressure decreases (mainly with intravenous administration). Weaker than atropine inhibits the secretion of the endocrine glands; causes a pronounced decrease in smooth muscle tone, amplitude and frequency of peristaltic contractions of the stomach, duodenum, small and large intestine, a moderate decrease in the tone of the gallbladder (in persons with biliary tract hyperkinesia);with hypokinesia - the tone of the gallbladder rises to a normal state. It relaxes the smooth muscles of the uterus, bladder and urinary tract; providing an antispasmodic effect, eliminates pain syndrome. Relaxes the smooth muscles of the bronchi, caused by an increase in the tone of n.vagus or anticholinergics, increases the volume of respiration, inhibits the secretion of the bronchial glands; reduces the tone of the sphincters.

When instilled into the conjunctival sac of the eye and parenteral administration, it causes pupil dilation due to relaxation of the circular muscle of the iris. At the same time, intraocular pressure rises and accommodation paralysis occurs (relaxation of the ciliary muscle of the ciliary body). In comparison with atropine, the effect on accommodation is less pronounced and shorter. It excites the brain and the respiratory center, to a greater extent - the spinal cord (in high doses, convulsions, depression of the central nervous system, vasomotor and respiratory centers are possible). Penetrates the BBB.

Side effect

From the digestive system: dry mouth, thirst, intestinal atony.

From the side of the cardiovascular system: lowering blood pressure, tachycardia.

From the side of the central nervous system and peripheral nervous system: excitation of the central nervous system, dizziness, dilated pupils, accommodation paralysis, headache, photophobia, convulsions, acute psychosis.

From the urinary system: difficulty urinating, urinary retention.

Others: lung atelectasis.

Adverse reactions are most likely with the use of high doses of platifillin.

Contraindications for use

Hypersensitivity to platyphyllin.

Application during pregnancy and lactation

There are no data on the safety of using platifillin during pregnancy and lactation (breastfeeding).

Application for violations of liver function

Use with caution in liver failure.

Application for impaired renal function

Use with caution in renal failure (risk of side effects due to reduced excretion).

Application in children

Use with caution in chronic lung diseases in young children (a decrease in bronchial secretion can lead to thickening of secretions and the formation of congestion in the bronchi); brain damage in children (effects from the central nervous system may increase); Down's disease (possibly an unusual dilation of the pupils and an increase in heart rate), cerebral palsy (the reaction to anticholinergics may be most pronounced).

special instructions

Use with caution in patients with diseases of the cardiovascular system, in which an increase in heart rate may be undesirable: atrial fibrillation, tachycardia, chronic heart failure, coronary artery disease, mitral stenosis, arterial hypertension, acute bleeding; with thyrotoxicosis (possibly increased tachycardia); elevated temperature (may even increase due to suppression of the activity of sweat glands); with reflux esophagitis, hernia of the esophageal opening of the diaphragm, combined with reflux esophagitis (decreased motility of the esophagus and stomach and relaxation of the lower esophageal sphincter can slow down gastric emptying and increase gastroesophageal reflux through the sphincter with impaired function); in diseases of the gastrointestinal tract, accompanied by obstruction - achalasia of the esophagus,pyloric stenosis (possibly decreased motility and tone, leading to obstruction and retention of stomach contents), intestinal atony in elderly or debilitated patients (obstruction may develop), paralytic intestinal obstruction; with an increase in intraocular pressure - angle-closure (the mydriatic effect, leading to an increase in intraocular pressure, can cause an acute attack) and open-angle glaucoma (the mydriatic effect may cause a slight increase in intraocular pressure; correction of therapy may be required); with nonspecific ulcerative colitis (high doses can inhibit intestinal motility, increasing the likelihood of paralytic intestinal obstruction, in addition, the manifestation or exacerbation of such a serious complication as toxic megacolon is possible);with dry mouth (prolonged use may further increase the severity of xerostomia); with liver failure (decreased metabolism) and renal failure (risk of side effects due to reduced excretion); with chronic lung diseases, especially in young children and debilitated patients (a decrease in bronchial secretion can lead to thickening of secretions and the formation of congestion in the bronchi); with myasthenia gravis (the condition may worsen due to inhibition of the action of acetylcholine); prostatic hypertrophy without urinary tract obstruction, urinary retention or predisposition to it, or diseases accompanied by urinary tract obstruction (including the bladder neck due to prostatic hypertrophy); with gestosis (possibly increased arterial hypertension);brain damage in children (effects from the central nervous system may increase); Down's disease (possibly an unusual dilation of the pupils and an increase in heart rate), cerebral palsy (the reaction to anticholinergics may be most pronounced).

Influence on the ability to drive vehicles and use mechanisms

It is necessary to refrain from potentially hazardous activities that require increased attention and speed of psychomotor reactions.

Drug interactions

With simultaneous use with haloperidol in patients with schizophrenia, a decrease in the antipsychotic effect is possible.

Platyphyllin is a proserin antagonist.

With simultaneous use, the duration of the hypnotic effect of phenobarbital, sodium ethaminal, magnesium sulfate increases.

With simultaneous use with other m-anticholinergics, as well as with drugs with m-anticholinergic activity (including amantadine, haloperidol, phenothiazine, MAO inhibitors, tricyclic antidepressants, some antihistamines), the risk of side effects increases.

Morphine enhances the inhibitory effect of platifillin on the cardiovascular system.

With simultaneous use with MAO inhibitors, a positive chrono- and batmotropic effect is observed; with cardiac glycosides - a positive batmotropic effect.

For pain associated with spasms of smooth muscles, the effect of platyphyllin is enhanced by analgesics, sedatives and anxiolytics, with vascular spasms - antihypertensive and sedatives.